Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study (Altered)
End Stage Renal Disease, Left Ventricular Hypertrophy
About this trial
This is an interventional treatment trial for End Stage Renal Disease focused on measuring Left Ventricular Hypertrophy, Allopurinol, End Stage Renal Disease, Haemodialysis, Renal Replacement Therapy, MRI
Eligibility Criteria
Inclusion Criteria:
- aged 18 years or over
- end stage renal disease (CKD stage 5 eGFR <15ml/min /1.73m2)
- been on haemodialysis for at least 3 months.
Exclusion Criteria:
- Known heart failure
- Left Ventricular Ejection Fraction <45%,
- active gout
- severe hepatic disease
- or on azathioprine, 6 mercaptopurine, theophylline.
- malignancy or other life threatening diseases,
- pregnant or lactating women
- any contraindication to MRI (claustrophobia, metal implants).
- with a planned (relative) kidney transplant,
- Patients who have participated in any other clinical trial within the previous 30 days will be excluded.
- Patients who are unable to give informed consent will also be excluded from this trial.
- Any other considered by a study physician to be inappropriate for inclusion
Sites / Locations
- NHS Greater Glasgow and Clyde
- NHS Tayside
- NHS Ayrshire and Arran
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Allopurinol
Placebo
Participants in this arm will be given allopurinol with the dose gradually increasing weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
Participants in this arm will be given placebo with the dose appearing to gradually increase weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.